Current antiplatelet therapies: benefits and limitations.
Antiplatelet therapy is the current criterion standard for the treatment of patients undergoing percutaneous coronary intervention and patients who have acute coronary syndromes. Clopidogrel in combination with aspirin is the current standard of care for reducing cardiovascular events in these patients. However, patients who receive currently available antiplatelet therapy may still develop atherothrombotic events. In addition, despite the clinical benefits achieved with clopidogrel, significant clinical limitations are associated with its use. This article summarizes the current understanding of the benefits and limitations of the commonly used antiplatelet therapies.
Am Heart J. 2008 Aug;156(2 Suppl):S3-9
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Cardiovascular Health|
|Article Type:||Brief article|
|Date:||Nov 1, 2008|
|Previous Article:||Association of lipoprotein-associated phospholipase A2 with coronary calcification among American and Japanese men.|
|Next Article:||Variability in response to cardiovascular drugs.|